Review of Novel Surgical, Radiation, and Systemic Therapies and Clinical Trials in Glioblastoma

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2024 Oct 16

PMID 39408897

Authors

Allison R Valerius

Lauren M Webb

Anna Thomsen

Eric J Lehrer

William G Breen

Jian L Campian

Cecile Riviere-Cazaux

Terry C Burns

Ugur Sener

Affiliations

Soon will be listed here.

Abstract

Glioblastoma (GBM) is the most common malignant primary brain tumor in adults. Despite an established standard of care including surgical resection, radiation therapy, and chemotherapy, GBM unfortunately is associated with a dismal prognosis. Therefore, researchers are extensively evaluating avenues to expand GBM therapy and improve outcomes in patients with GBM. In this review, we provide a broad overview of novel GBM therapies that have recently completed or are actively undergoing study in clinical trials. These therapies expand across medical, surgical, and radiation clinical trials. We additionally review methods for improving clinical trial design in GBM.

Citing Articles

Targeting EGFR and PI3K/mTOR pathways in glioblastoma: innovative therapeutic approaches.

Singh G, Rohit , Kumar P, Aran K Med Oncol. 2025; 42(4):97.

PMID: 40064710 DOI: 10.1007/s12032-025-02652-1.

Comparative Clinical-Imaging and Histogenetic Analysis Between Astrocytoma IDH-Mutant Grade 4 and Glioblastoma IDH-Wildtype-Is There Really a Worse One?.

Orasanu C, Aschie M, Deacu M, Bosoteanu M, Vamesu S, Enciu M Diagnostics (Basel). 2025; 15(4).

PMID: 40002588 PMC: 11854731. DOI: 10.3390/diagnostics15040438.

Glioblastoma Cell Migration, Invasion and Vasculogenic Mimicry Downmodulated by Novel uPAcyclin Derivatives.

Santoro F, Merlino F, Brancaccio D, Camerino I, Belli S, Cimmino A Cells. 2025; 14(4).

PMID: 39996732 PMC: 11853379. DOI: 10.3390/cells14040259.

References

Bao S, Wu Q, McLendon R, Hao Y, Shi Q, Hjelmeland A . Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 2006; 444(7120):756-60. DOI: 10.1038/nature05236. View

Patyal B . Dosimetry aspects of proton therapy. Technol Cancer Res Treat. 2007; 6(4 Suppl):17-23. DOI: 10.1177/15330346070060S403. View

Hovey E, Field K, Rosenthal M, Barnes E, Cher L, Nowak A . Continuing or ceasing bevacizumab beyond progression in recurrent glioblastoma: an exploratory randomized phase II trial. Neurooncol Pract. 2019; 4(3):171-181. PMC: 6655481. DOI: 10.1093/nop/npw025. View

Sener U, Ruff M, Campian J . Immunotherapy in Glioblastoma: Current Approaches and Future Perspectives. Int J Mol Sci. 2022; 23(13). PMC: 9266573. DOI: 10.3390/ijms23137046. View

SUGAWA N, Ekstrand A, James C, Collins V . Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas. Proc Natl Acad Sci U S A. 1990; 87(21):8602-6. PMC: 55005. DOI: 10.1073/pnas.87.21.8602. View

Sim H, Galanis E, Khasraw M . PARP Inhibitors in Glioma: A Review of Therapeutic Opportunities. Cancers (Basel). 2022; 14(4). PMC: 8869934. DOI: 10.3390/cancers14041003. View

Fitzgerald C, Dogan S, Bou-Nassif R, Mclean T, Woods R, Cracchiolo J . Stimulated Raman Histology for Rapid Intra-Operative Diagnosis of Sinonasal and Skull Base Tumors. Laryngoscope. 2022; 132(11):2142-2147. PMC: 10291728. DOI: 10.1002/lary.30233. View

Drilon A, Siena S, Ou S, Patel M, Ahn M, Lee J . Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1). Cancer Discov. 2017; 7(4):400-409. PMC: 5380583. DOI: 10.1158/2159-8290.CD-16-1237. View

Barbato M, Nashed J, Bradford D, Ren Y, Khasar S, Miller C . FDA Approval Summary: Dabrafenib in Combination with Trametinib for BRAFV600E Mutation-Positive Low-Grade Glioma. Clin Cancer Res. 2023; 30(2):263-268. PMC: 10841289. DOI: 10.1158/1078-0432.CCR-23-1503. View

10.

Liu Y, Wong C, Ding Y, Gao M, Wen J, Lau H . Peptostreptococcus anaerobius mediates anti-PD1 therapy resistance and exacerbates colorectal cancer via myeloid-derived suppressor cells in mice. Nat Microbiol. 2024; 9(6):1467-1482. PMC: 11153135. DOI: 10.1038/s41564-024-01695-w. View

11.

van den Bent M, Eoli M, Sepulveda J, Smits M, Walenkamp A, Frenel J . INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma. Neuro Oncol. 2019; 22(5):684-693. PMC: 7229258. DOI: 10.1093/neuonc/noz222. View

12.

Ahmed N, Brawley V, Hegde M, Bielamowicz K, Kalra M, Landi D . HER2-Specific Chimeric Antigen Receptor-Modified Virus-Specific T Cells for Progressive Glioblastoma: A Phase 1 Dose-Escalation Trial. JAMA Oncol. 2017; 3(8):1094-1101. PMC: 5747970. DOI: 10.1001/jamaoncol.2017.0184. View

13.

Lu V, Jue T, McDonald K, Rovin R . The Survival Effect of Repeat Surgery at Glioblastoma Recurrence and its Trend: A Systematic Review and Meta-Analysis. World Neurosurg. 2018; 115:453-459.e3. DOI: 10.1016/j.wneu.2018.04.016. View

14.

Stummer W, Pichlmeier U, Meinel T, Wiestler O, Zanella F, Reulen H . Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol. 2006; 7(5):392-401. DOI: 10.1016/S1470-2045(06)70665-9. View

15.

Riviere-Cazaux C, Lacey J, Carlstrom L, Laxen W, Munoz-Casabella A, Hoplin M . Cerebrospinal fluid 2-hydroxyglutarate as a monitoring biomarker for IDH-mutant gliomas. Neurooncol Adv. 2023; 5(1):vdad061. PMC: 10259246. DOI: 10.1093/noajnl/vdad061. View

16.

Lehrer E, McGee H, Peterson J, Vallow L, Ruiz-Garcia H, Zaorsky N . Stereotactic Radiosurgery and Immune Checkpoint Inhibitors in the Management of Brain Metastases. Int J Mol Sci. 2018; 19(10). PMC: 6213912. DOI: 10.3390/ijms19103054. View

17.

McCracken D, Schupper A, Lakomkin N, Malcolm J, Bray D, Hadjipanayis C . Turning on the light for brain tumor surgery: A 5-aminolevulinic acid story. Neuro Oncol. 2022; 24(Suppl 6):S52-S61. PMC: 9629477. DOI: 10.1093/neuonc/noac191. View

18.

Kievit F, Wang K, Ozawa T, Tarudji A, Silber J, Holland E . Nanoparticle-mediated knockdown of DNA repair sensitizes cells to radiotherapy and extends survival in a genetic mouse model of glioblastoma. Nanomedicine. 2017; 13(7):2131-2139. PMC: 6002851. DOI: 10.1016/j.nano.2017.06.004. View

19.

Rahman R, Trippa L, Lee E, Arrillaga-Romany I, Fell G, Touat M . Inaugural Results of the Individualized Screening Trial of Innovative Glioblastoma Therapy: A Phase II Platform Trial for Newly Diagnosed Glioblastoma Using Bayesian Adaptive Randomization. J Clin Oncol. 2023; 41(36):5524-5535. DOI: 10.1200/JCO.23.00493. View

20.

Cohen M, Shen Y, Keegan P, Pazdur R . FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme. Oncologist. 2009; 14(11):1131-8. DOI: 10.1634/theoncologist.2009-0121. View